메뉴 건너뛰기




Volumn 10, Issue 8, 2015, Pages 1172-1180

Inhibiting MDM2-p53 interaction suppresses tumor growth in patient-derived non-small cell lung cancer xenograft models

Author keywords

MDM2 inhibitor; Non small cell lung cancer; P53; Patient derived xenografts.; RG7388

Indexed keywords

IDASANUTLIN; KI 67 ANTIGEN; PROTEIN MDM2; PROTEIN P53; 4 AMINOBENZOIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; PYRROLIDINE DERIVATIVE;

EID: 84942891468     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000584     Document Type: Article
Times cited : (37)

References (31)
  • 2
    • 84878046514 scopus 로고    scopus 로고
    • Survival of patients with non-small cell lung cancer without treatment: A systematic review and meta-Analysis
    • Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-Analysis. Syst Rev 2013;2:10.
    • (2013) Syst Rev , vol.2 , pp. 10
    • Wao, H.1    Mhaskar, R.2    Kumar, A.3    Miladinovic, B.4    Djulbegovic, B.5
  • 3
    • 15744362912 scopus 로고    scopus 로고
    • The 2004 world health organization classification of lung tumors
    • Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005;40:90-97.
    • Semin Roentgenol , vol.2005 , Issue.40 , pp. 90-97
    • Beasley, M.B.1    Brambilla, E.2    Travis, W.D.3
  • 4
    • 84879071011 scopus 로고    scopus 로고
    • Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    • Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
    • (2013) N Engl J Med , vol.368 , pp. 2385-2394
    • Shaw, A.T.1    Kim, D.W.2    Nakagawa, K.3
  • 5
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre open-label randomised phase 3 trial
    • Spanish Lung Cancer Group in Collaboration with Groupe Franais de Pneumo-Cancrologie and Associazione Italiana Oncologia Toracica
    • Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group in Collaboration with Groupe Franais de Pneumo-Cancrologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
    • (2012) Lancet Oncol , vol.13 , pp. 239-246
    • Rosell, R.1    Carcereny, E.2    Gervais, R.3
  • 6
    • 0037816165 scopus 로고    scopus 로고
    • Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis
    • Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003;100:8424-8429.
    • (2003) Proc Natl Acad Sci U S A , vol.100 , pp. 8424-8429
    • Kato, S.1    Han, S.Y.2    Liu, W.3
  • 7
    • 0030905284 scopus 로고    scopus 로고
    • Mdm2 promotes the rapid degradation of p53
    • Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
    • (1997) Nature , vol.387 , pp. 296-299
    • Haupt, Y.1    Maya, R.2    Kazaz, A.3    Oren, M.4
  • 8
    • 0031583962 scopus 로고    scopus 로고
    • Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
    • Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-27.
    • (1997) FEBS Lett , vol.420 , pp. 25-27
    • Honda, R.1    Tanaka, H.2    Yasuda, H.3
  • 9
    • 84905029258 scopus 로고    scopus 로고
    • Comprehensive molecular profiling of lung adenocarcinoma
    • Cancer Genome Atlas Research Network
    • Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-450.
    • (2014) Nature , vol.511 , pp. 543-550
  • 10
    • 84866894408 scopus 로고    scopus 로고
    • Comprehensive genomic characterization of squamous cell lung cancers
    • Cancer Genome Atlas Research Network
    • Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-525.
    • (2012) Nature , vol.489 , pp. 519-525
  • 11
    • 0029806936 scopus 로고    scopus 로고
    • Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53
    • Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-432.
    • (1996) Science , vol.274 , pp. 430-432
    • Denissenko, M.F.1    Pao, A.2    Tang, M.3    Pfeifer, G.P.4
  • 12
    • 77955363995 scopus 로고    scopus 로고
    • TP53 mutations in human cancers: Origins, consequences, and clinical use
    • Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010;2:a001008.
    • (2011) Cold Spring Harb Perspect Biol , vol.2 , pp. a001008
    • Olivier, M.1    Hollstein, M.2    Hainaut, P.3
  • 15
    • 84876914265 scopus 로고    scopus 로고
    • MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models
    • Tovar C, Graves B, Packman K, et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 2013;73:2587-2597.
    • (2013) Cancer Res , vol.73 , pp. 2587-2597
    • Tovar, C.1    Graves, B.2    Packman, K.3
  • 16
    • 84868203735 scopus 로고    scopus 로고
    • Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-Amplified, welldifferentiated or dedifferentiated liposarcoma: An exploratory proof-ofmechanism study
    • Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-Amplified, welldifferentiated or dedifferentiated liposarcoma: an exploratory proof-ofmechanism study. Lancet Oncol 2012;13:1133-1140.
    • (2012) Lancet Oncol , vol.13 , pp. 1133-1140
    • Ray-Coquard, I.1    Blay, J.Y.2    Italiano, A.3
  • 17
    • 84880896065 scopus 로고    scopus 로고
    • Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
    • Ding Q, Zhang Z, Liu JJ, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 2013;56:5979-5983.
    • (2013) J Med Chem , vol.56 , pp. 5979-5983
    • Ding, Q.1    Zhang, Z.2    Liu, J.J.3
  • 18
    • 0141566685 scopus 로고    scopus 로고
    • Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models
    • Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-4239.
    • (2003) Clin Cancer Res , vol.9 , pp. 4227-4239
    • Voskoglou-Nomikos, T.1    Pater, J.L.2    Seymour, L.3
  • 19
    • 65949099336 scopus 로고    scopus 로고
    • A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro
    • Daniel VC, Marchionni L, Hierman JS, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009;69:3364-3373.
    • (2009) Cancer Res , vol.69 , pp. 3364-3373
    • Daniel, V.C.1    Marchionni, L.2    Hierman, J.S.3
  • 20
    • 34548217651 scopus 로고    scopus 로고
    • Maximizing mouse cancer models
    • Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007;7:645-658.
    • (2007) Nat Rev Cancer , vol.7 , pp. 645-658
    • Frese, K.K.1    Tuveson, D.A.2
  • 21
    • 78751471036 scopus 로고    scopus 로고
    • The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in earlystage non-small cell lung cancer
    • John T, Kohler D, Pintilie M, et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in earlystage non-small cell lung cancer. Clin Cancer Res 2011;17:134-141.
    • (2011) Clin Cancer Res , vol.17 , pp. 134-141
    • John, T.1    Kohler, D.2    Pintilie, M.3
  • 22
    • 84899475102 scopus 로고    scopus 로고
    • Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts
    • Topp MD, Hartley L, Cook M, et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol 2014;8:656-668.
    • (2014) Mol Oncol , vol.8 , pp. 656-668
    • Topp, M.D.1    Hartley, L.2    Cook, M.3
  • 23
    • 84886598463 scopus 로고    scopus 로고
    • Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma
    • Craddock KJ, Ludkovski O, Sykes J, Shepherd FA, Tsao MS. Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma. J Thorac Oncol 2013;8:1371-1377.
    • (2013) J Thorac Oncol , vol.8 , pp. 1371-1377
    • Craddock, K.J.1    Ludkovski, O.2    Sykes, J.3    Shepherd, F.A.4    Tsao, M.S.5
  • 24
    • 78649680251 scopus 로고    scopus 로고
    • Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer
    • Zhu CQ, Ding K, Strumpf D, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010;28:4417-4424.
    • (2011) J Clin Oncol , vol.28 , pp. 4417-4424
    • Zhu, C.Q.1    Ding, K.2    Strumpf, D.3
  • 25
    • 34248379012 scopus 로고    scopus 로고
    • Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database
    • Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-629.
    • (2007) Hum Mutat , vol.28 , pp. 622-629
    • Petitjean, A.1    Mathe, E.2    Kato, S.3
  • 26
    • 33846935466 scopus 로고    scopus 로고
    • Cancer biology: Gone but not forgotten
    • Sharpless NE, DePinho RA. Cancer biology: gone but not forgotten. Nature 2007;445:606-607.
    • (2007) Nature , vol.445 , pp. 606-607
    • Sharpless, N.E.1    DePinho, R.A.2
  • 27
    • 84874948475 scopus 로고    scopus 로고
    • A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis
    • Kracikova M, Akiri G, George A, Sachidanandam R, Aaronson SA. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ 2013;20:576-588.
    • (2013) Cell Death Differ , vol.20 , pp. 576-588
    • Kracikova, M.1    Akiri, G.2    George, A.3    Sachidanandam, R.4    Aaronson, S.A.5
  • 28
    • 84871939847 scopus 로고    scopus 로고
    • Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer
    • Xu J, Knox JJ, Ibrahimov E, et al. Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer. Clin Cancer Res 2013;19:118-127.
    • (2013) Clin Cancer Res , vol.19 , pp. 118-127
    • Xu, J.1    Knox, J.J.2    Ibrahimov, E.3
  • 29
    • 32444449180 scopus 로고    scopus 로고
    • Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
    • Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103:1888-1893.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 1888-1893
    • Tovar, C.1    Rosinski, J.2    Filipovic, Z.3
  • 30
    • 26444560960 scopus 로고    scopus 로고
    • Caspases: Pharmacological manipulation of cell death
    • Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005;115:2665-2672.
    • (2005) J Clin Invest , vol.115 , pp. 2665-2672
    • Lavrik, I.N.1    Golks, A.2    Krammer, P.H.3
  • 31
    • 84868209130 scopus 로고    scopus 로고
    • A phase i study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors
    • abstr e13600
    • Kurzrock R, Blay J-Y, Nguyen BB, et al. A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. Proc Am Soc Clin Oncol 2012;30 (Suppl):abstr e13600.
    • (2012) Proc Am Soc Clin Oncol , vol.30
    • Kurzrock, R.1    Blay, J.-Y.2    Nguyen, B.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.